A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
收藏DataCite Commons2025-02-07 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003908/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.
提供机构：
Vivli
创建时间：
2019-05-07
